BCYC

Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences

OXURION NV to Present at Wet AMD and DME Drug Development Summit

Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?

Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD

Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

OXURION to Participate in Upcoming Investor Meetings